Clinical trials: Leukemia, Acute Lymphoblastic
B-cell Acute Lymphoblastic Leukemia
Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk
Previous findings have shown that a biomarker comprised of the three microRNAs (miRs) miR-451, miR-151-5p and miR-1290 can independently predict precursor B-cell acute lymphoblastic leukemia (B- ALL) patients' risk for relapse…
- Trial name
- NCT03000335
- Where
- 2 sites in Israel
- Volunteers
- 65 people
- Sponsor
- Curewize Health Ltd.
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia
The objective of this study is to determine the efficacy and safety of imatinib mesylate in patients diagnosed as having Philadelphia chromosome positive acute lymphocytic leukemia (ALL).
- Trial name
- NCT00154349
- Testing
- Imatinib Mesylate
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic lymphoblastic leukemia, and to obtain the…
- Trial name
- NCT06082596
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- BeBetter Med Inc
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT01744223
- Testing
- BPX-501 dose 1, Rimiducid, BPX-501 dose 2
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bellicum Pharmaceuticals
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
Study CR-AIR-006 is a part of the ATIR clinical development plan and will provide control data for patients treated with ATIR in clinical studies (e.g. study CR-AIR-007).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02188290
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 178 people
- Sponsor
- Kiadis Pharma
B Acute Lymphoblastic Leukemia/Lymphoma
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
- Trial name
- NCT07196111
- Testing
- BAFFR CAR-T
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL.
- Conditions
- Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
- Trial name
- NCT05885464
- Testing
- BEAM-201
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Beam Therapeutics Inc.
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
- Trial name
- NCT04703192
- Testing
- Valemetostat Tosylate
- Where
- 60 sites in United States, Australia and 10 more
- Volunteers
- 155 people
- Sponsor
- Daiichi Sankyo
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT00384228
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory…
- Trial name
- NCT03476239
- Testing
- Blinatumomab, Dexamthasone
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- Amgen
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Expanded Access Program of Ponatinib
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available…
- Trial name
- NCT01592136
- Testing
- ponatinib
- Where
- 33 sites in United States
- Sponsor
- Ariad Pharmaceuticals
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
This is a single arm, open-label study to evaluate the safety and efficacy of humanized anti-CD19 CAR-T cells in patients with relapsed or refractory B cell Malignancies.
- Trial name
- NCT04008251
- Testing
- Second generation humanized CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.
- Conditions
- Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT03263637
- Testing
- AZD4573
- Where
- 12 sites in Germany, Netherlands and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
A retrospective analysis of historical data looking at hematological remission and survival in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.
- Trial name
- NCT02003612
- Testing
- Not applicable - observational study
- Where
- 10 sites in United States, Czechia and 6 more
- Volunteers
- 2,373 people
- Sponsor
- Amgen
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
This research study tests an investigational drug called DS-3201b. An investigational drug is a medication that is still being studied and has not yet been approved by the United States Food and Drug Administration (FDA).
- Trial name
- NCT03110354
- Testing
- DS-3201b
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03833180
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)